Related references
Note: Only part of the references are listed.Hallmarks of Cancer: New Dimensions
Douglas Hanahan
CANCER DISCOVERY (2022)
Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells
Lindsey M. Ludwig et al.
CELL DEATH & DISEASE (2021)
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity
Lisa R. Volpatti et al.
ACS CENTRAL SCIENCE (2021)
Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma
Victoria M. Smith et al.
HAEMATOLOGICA (2020)
Loss of BIM in T cells results in BCL-2 family BH3-member compensation but incomplete cell death sensitivity normalization
Lindsey M. Ludwig et al.
APOPTOSIS (2020)
p53 programmes plough on
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2020)
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors
Thomas P. Howard et al.
CANCER RESEARCH (2019)
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma
Mathilde Rikje Willemijn de Jong et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Activating the Intrinsic Pathway of Apoptosis Using BIM BH3 Peptides Delivered by Peptide Amphiphiles with Endosomal Release
Mathew R. Schnorenberg et al.
MATERIALS (2019)
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
Rumani Singh et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Targeting the Bcl-2 Family in B Cell Lymphoma
Clare M. Adams et al.
FRONTIERS IN ONCOLOGY (2019)
Stereoisomerism of stapled peptide inhibitors of the p53-Mdm2 interaction: an assessment of synthetic strategies and activity profiles
Tsz Ying Yuen et al.
CHEMICAL SCIENCE (2019)
Polymersomes scalably fabricated via flash nano-precipitation are non-toxic in non-human primates and associate with leukocytes in the spleen and kidney following intravenous administration
Sean D. Allen et al.
NANO RESEARCH (2018)
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Matej Horvat et al.
ONCOLOGY LETTERS (2018)
Genome-scale CRI SPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
Bjorn Stolte et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Synthesis and Purification of Homogeneous Lipid-Based Peptide Nanocarriers by Overcoming Phospholipid Ester Hydrolysis
Mathew R. Schnorenberg et al.
ACS OMEGA (2018)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Facile assembly and loading of theranostic polymersomes via multi-impingement flash nanoprecipitation
Sean Allen et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
Alan Van Goethem et al.
ONCOTARGET (2017)
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy
Rongqing Pan et al.
CANCER CELL (2017)
Cathepsin-Mediated Cleavage of Peptides from Peptide Amphiphiles Leads to Enhanced Intracellular Peptide Accumulation
Handan Acar et al.
BIOCONJUGATE CHEMISTRY (2017)
Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices
Gregory H. Bird et al.
NATURE CHEMICAL BIOLOGY (2016)
Clinical Overview of MDM2/X-Targeted Therapies
Andrew Burgess et al.
FRONTIERS IN ONCOLOGY (2016)
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Alex R. D. Delbridge et al.
NATURE REVIEWS CANCER (2016)
Double Strain-Promoted Macrocyclization for the Rapid Selection of Cell-Active Stapled Peptides
Yu Heng Lau et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
Towards understanding cell penetration by stapled peptides
Qian Chu et al.
MEDCHEMCOMM (2015)
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
D. C. Phillips et al.
BLOOD CANCER JOURNAL (2015)
p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression A Single Institutional Clinicopathologic Study
Yi Xie et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2014)
Novel aspects of encapsulation and delivery using polymersomes
Lea Messager et al.
CURRENT OPINION IN PHARMACOLOGY (2014)
BH3 profiling in whole cells by fluorimeter or FACS
Jeremy Ryan et al.
METHODS (2013)
Stapled α-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy
Yong S. Chang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Dendritic cell activation and T cell priming with adjuvant- and antigen-loaded oxidation-sensitive polymersomes
Evan A. Scott et al.
BIOMATERIALS (2012)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma
Stefano Monti et al.
CANCER CELL (2012)
A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
James L. LaBelle et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A simple confined impingement jets mixer for flash nanoprecipitation
Jing Han et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2012)
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival
Karen Y. Dane et al.
JOURNAL OF CONTROLLED RELEASE (2011)
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21)
E. Drakos et al.
LEUKEMIA (2011)
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3
Michele Dal Bo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Federico Bernal et al.
CANCER CELL (2010)
The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment
W. W. Cheng et al.
EXPERT OPINION ON DRUG DELIVERY (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: Cross-presentation and T cell activation
Sachiko Hirosue et al.
VACCINE (2010)
A Novel Method for the Encapsulation of Biomolecules into Polymersomes via Direct Hydration
Conlin P. O'Neil et al.
LANGMUIR (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor
Christin Tse et al.
CANCER RESEARCH (2008)
Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv
Wilson W. K. Cheng et al.
JOURNAL OF CONTROLLED RELEASE (2008)
Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning
Thomas Tiller et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
PEG-b-PPS diblock copolymer aggregates for hydrophobic drug solubilization and release:: Cyclosporin A as an example
Diana Velluto et al.
MOLECULAR PHARMACEUTICS (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
PEG-SS-PPS: Reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery
Simona Cerritelli et al.
BIOMACROMOLECULES (2007)
Programmed anuclear cell death delimits platelet life span
Kylie D. Mason et al.
CELL (2007)
Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide
Federico Bernal et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
The p53-Bcl-2 connection
M. T. Hemann et al.
CELL DEATH AND DIFFERENTIATION (2006)
In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles
ST Reddy et al.
JOURNAL OF CONTROLLED RELEASE (2006)
Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates
TM Allen et al.
CLINICAL CANCER RESEARCH (2005)
Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes
P Sapra et al.
CLINICAL CANCER RESEARCH (2004)
Oxidation-responsive polymeric vesicles
A Napoli et al.
NATURE MATERIALS (2004)
Polymer vesicles in vivo: correlations with PEG molecular weight
PJ Photos et al.
JOURNAL OF CONTROLLED RELEASE (2003)
Lyotropic behavior in water of amphiphilic ABA triblock copolymers based on poly(propylene sulfide) and poly(ethylene glycol)
A Napoli et al.
LANGMUIR (2002)
Structural identification of a key protective B-cell epitope in lyme disease antigen OspA
W Ding et al.
JOURNAL OF MOLECULAR BIOLOGY (2000)
Share Paper
